« Back to Record
Citation APA

Pannus, P., Depickère, S., Kemlin, D., Houben, S., Neven, K. Y., Heyndrickx, L., Michiels, J., Willems, E., De Craeye, S., Francotte, A., Chaumont, F., Olislagers, V., Waegemans, A., Verbrugghe, M., Schmickler, M.-N., Van Gucht, S., Dierick, K., Marchant, A., Desombere, I., Ariën, K. K., & Goossens, M. M. (2022). Safety and immunogenicity of a reduced dose of the BNT162b2 mRNA COVID-19 vaccine (REDU-VAC): A single blind, randomized, non-inferiority trial. PLOS global public health, 2(12), e0001308. doi:10.1371/journal.pgph.0001308


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/357920

Pannus, P., Depickère, S., Kemlin, D., Houben, S., Neven, K. Y., Heyndrickx, L., Michiels, J., Willems, E., De Craeye, S., Francotte, A., Chaumont, F., Olislagers, V., Waegemans, A., Verbrugghe, M., Schmickler, M.-N., Van Gucht, S., Dierick, K., Marchant, A., Desombere, I., Ariën, K. K., & Goossens, M. M. (2022). Safety and immunogenicity of a reduced dose of the BNT162b2 mRNA COVID-19 vaccine (REDU-VAC): A single blind, randomized, non-inferiority trial. PLOS global public health, 2(12), e0001308. doi:10.1371/journal.pgph.0001308